LX1031: Phase II started

Lexicon began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 250 and 1,000 mg of oral LX1031 given 4 times daily for 4 weeks in up to 150 patients with diarrhea-predominant or mix...